Trials / Completed
CompletedNCT05445232
A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
A Multiple-Dose Drug-Drug Interaction Study to Determine the Effect of LY3437943 on Drug Metabolizing Enzymes
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to determine the effect of LY3437943 when administered subcutaneously on the levels of midazolam, warfarin and caffeine in the blood stream when administered orally as a drug cocktail in obese participants. This study will last up to approximately 25 weeks for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3437943 | Administered SC. |
| DRUG | Midazolam | Administered orally. |
| DRUG | Warfarin | Administered orally. |
| DRUG | Caffeine | Administered orally. |
Timeline
- Start date
- 2022-07-08
- Primary completion
- 2023-02-24
- Completion
- 2023-02-24
- First posted
- 2022-07-06
- Last updated
- 2023-04-18
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05445232. Inclusion in this directory is not an endorsement.